Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline. RESEARCH DESIGN AND METHODS: Subanalysis of a phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI ≥27 to ≤45 kg/m2) with two or more comorbidities. Subjects were randomized to placebo, PHEN 7.5 mg/TPM ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92) plus lifestyle modifications for 108 weeks. Percent weight loss in the intent-to-treat population using multiple imputation (ITT-MI), annualized incidence rate of progression to type 2 diabetes, and changes in glycemia, lipid parameters, blood pressure, and waist circumference were evaluated. RESULTS: At baseline, 475 subjects met the criteria for prediabetes and/or MetS. After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo. The ability of PHEN/TPM ER to prevent diabetes was related to degree of weight lost and was accompanied by significant improvements in cardiometabolic parameters. PHEN/TPM ER was well tolerated by this subgroup over 2 years. CONCLUSIONS: PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a post hoc CONQUER analysis, phentermine/topiramate ER reduced T2D progression by 48–78% over 56 weeks, depending on dose and baseline glycemia, driven by up to 10.9% weight loss and improved insulin sensitivity [26].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This agent induces significant weight loss (10–12%) [26] which may alleviate OA symptoms. However, OA-specific data are lacking, and use remains extrapolative.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The translation of the structured lifestyle intervention used in the Diabetes Prevention Program to community-based programs, commercial programs, and programs using remote technologies have achieved less weight loss than observed in the Diabetes Prevention Program trial itself.861–869”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [865]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A meta-analysis of 44 Diabetes Prevention Program translation studies reported an average 9.3-month weight loss of 3.77 kg from participants’ baseline weight and a decrease in fasting glucose of 2.4 mg/dL.865”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [865]
Experimental — accuracy not yet measuredIn the citing paper
“Phentermine/topiramate ER reduced incident T2DM in patients with prediabetes or metabolic syndrome by 79%.”
From The Vasculature in Prediabetes (2018) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 7×
“The DPP study, wherein patients achieved ;6% mean weight loss at 2 years and ;4% weight loss at 4 years in the lifestyle intervention arm, reported a progressive 16% reduction in type 2 diabetes risk with every kilogram of weight loss but without an indication that there was a threshold of weight loss for maximal type…”
BackgroundMethodInfluentialAlberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Analysis of Incomplete Multivariate Data
Booth, D. E. (2000) · Technometrics · doi:10.1080/00401706.2000.10486013 · Cited by 5,627
Research works printed but not linked: 2
- 27. Brownell K. The LEARN Program for Weight Management. Dallas, TX, The Life Style Company, 2000
- 40. Garvey WT, Najarian T, Peterson CA. Significant weight loss with controlled-release phentermine/topiramate (PHEN/TPM CR) is associated with significant reductions in use of concomitant medications for cardiometabolic diseases over 108 weeks. Obesity 2011;19:S176
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationNutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496
Self-citationThe Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
“Whether achieved through lifestyle therapy, pharmacotherapy, surgery, or some combination thereof, weight loss reduces insulin resistance and can effectively prevent progression to diabetes as well as improve plasma lipid profile and BP (44,48,49,51,53,60,63).”
BackgroundSelf-citationle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationMechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.10.025 · Cited by 608
Self-citationGarber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citationMechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0406 · Cited by 510
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“These agents improve BP and lipids, prevent progression to diabetes during trial periods, and improve glycemic control and lipids in patients with T2D (46-63).”
BackgroundSelf-citationMechanick, J. I., Apovian, C., Brethauer, S., Timothy Garvey, W., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah‐Pollack, R., Seger, J., et al. (2020) · Obesity · doi:10.1002/oby.22719 · Cited by 389
Self-citationSamson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Haw, J. S., Galaviz, K. I., Straus, A. N., Kowalski, A. J., Magee, M. J., Weber, M. B., Wei, J., Narayan, K. M. V., & Ali, M. K. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.6040 · Cited by 354
“Our study expands this evidence by including combined phenterminetopiramate, a newer antiobesity drug.(56) We showed that weight-loss medications, followed by insulin sensitizers, achieved thegreatest diabetes risk reductions.”
BackgroundGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“Whether achieved through lifestyle therapy alone or a combination of lifestyle therapy with pharmacotherapy and/or surgery, weight loss reduces insulin resistance and can effectively prevent progression to diabetes as well as improve plasma lipid profile and BP (49,53,54,56,58,65,68).”
BackgroundSelf-citationCefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
Self-citationAmerican Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s008 · Cited by 244
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s008 · Cited by 244
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s008 · Cited by 236
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s003 · Cited by 204
3. Prevention or Delay of Type 2 Diabetes:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s003 · Cited by 200
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s008 · Cited by 213
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Van Gaal, L. F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 190
Boutari, C., DeMarsilis, A., & Mantzoros, C. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110773 · Cited by 161
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s003 · Cited by 144
Kim, K.-K., Haam, J.-H., Kim, B. T., Kim, E. M., Park, J. H., Rhee, S. Y., Jeon, E., Kang, E., Nam, G. E., Koo, H. Y., et al. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23016 · Cited by 158
Lipoprotein Insulin Resistance Index: A Lipoprotein Particle–Derived Measure of Insulin Resistance
Shalaurova, I., Connelly, M. A., Garvey, W. T., & Otvos, J. D. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0050 · Cited by 176
“5 Although there are a number of methods that can be used to assess insulin sensitivity/resistance, 8 many are costly and time consuming, limiting their use in the primary care setting.”
Self-citationTherapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, A. B., & Shoelson, S. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88884 · Cited by 172
“org Volume 127 Number 1 January 2017 and phentermine/topiramate (37), which raises adiponectin.”
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s003 · Cited by 132
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s003 · Cited by 144
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s008 · Cited by 149
3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s003 · Cited by 162
Obesity and Chronic Pain: Systematic Review of Prevalence and Implications for Pain Practice
Narouze, S., & Souzdalnitski, D. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000218 · Cited by 148
“Topiramate, on the other hand, which is currently approved for migraine prevention, may avert compulsive eating in obese patients, which is one reason that it is currently approved for the treatment of obesity as a part of the previously discussed combination.(174) Some membrane stabilizers, such as zonisamide, may fa…”
BackgroundAmerican Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s008 · Cited by 158
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s008 · Cited by 148
Sarkar, S., Das, D., Dutta, P., Kalita, J., Wann, S. B., & Manna, P. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116594 · Cited by 159
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Self-citationNadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Self-citationLong-Term Weight Loss Strategies for Obesity
Kheniser, K., Saxon, D. R., & Kashyap, S. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab091 · Cited by 139
The Vasculature in Prediabetes
Wasserman, D. H., Wang, T. J., & Brown, N. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.311912 · Cited by 137
“Phentermine/topiramate ER reduced incident T2DM in patients with prediabetes or metabolic syndrome by 79%.(193) Bariatric surgery reduces incident diabetes mellitus not only through weight loss but through effects on incretin hormones, bile acids, or gut microflora.”
BackgroundSingh, A. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1698291 · Cited by 130
“7% reduction in developing incidental diabetes in patients with pre-diabetes or metabolic syndrome [54].”
BackgroundGrams, J. M., & Garvey, W. T. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0155-x · Cited by 145
Self-citation3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s003 · Cited by 124
Pharmacological approaches to the prevention of type 2 diabetes mellitus
Majety, P., Orquera, F. A. L., Edem, D., & Hamdy, O. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1118848 · Cited by 149
Metabolic syndrome in type 2 diabetic patients: a review of current evidence
Regufe, V. M. G., Pinto, C., & Perez, P. M. V. H. C. (2020) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000101 · Cited by 141
“3 individuals with MS are 5 times more likely to develop type 2 diabetes.(3,12,13) Type 2 diabetes is a rising global health problem.”
BackgroundBajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s008 · Cited by 165
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N., Meschik, J., & Semlitsch, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub4 · Cited by 104
Horn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Self-citationGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Mechanick, J. I., Garber, A. J., Grunberger, G., Handelsman, Y., & Garvey, W. T. (2018) · Endocrine Practice · doi:10.4158/ps-2018-0139 · Cited by 104
Self-citationAlfaris, N., Alqahtani, A. M., Alamuddin, N., & Rigas, G. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.03.002 · Cited by 116
Salameh, T. S., Shah, G. N., Price, T. O., Hayden, M. R., & Banks, W. A. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237057 · Cited by 100
“Topiramate shows promise despite some adverse side effects (Stenlof et al., 2007; Henry et al., 2013; Moradi et al., 2013; Garvey et al., 2014).”
BackgroundElkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab408 · Cited by 96
Health Benefits of Long-Term Weight-Loss Maintenance
Rueda-Clausen, C. F., Ogunleye, A. A., & Sharma, A. M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034434 · Cited by 91
Hsueh, W., McLellan, K., Wyne, K., & Villagomez, E. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s39564 · Cited by 91
“loss, without suggesting a direct effect of the combination of the phentermine plus topiramate.(174,175) Garvey et al(174)”
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2022) · Diabetes Care · doi:10.2337/dc21-1785 · Cited by 87
Kassaian, N., Feizi, A., Aminorroaya, A., & Amini, M. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.07.016 · Cited by 78
2014 EASO Position Statement on the Use of Anti-Obesity Drugs
Toplak, H., Woodward, E., Yumuk, V., Oppert, J.-M., Halford, J. C. G., & Frühbeck, G. (2015) · Obesity Facts · doi:10.1159/000430801 · Cited by 83
Self-citationMoon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 104
Tolerability and Safety of the New Anti-Obesity Medications
Hainer, V., & Aldhoon-Hainerová, I. (2014) · Drug Safety · doi:10.1007/s40264-014-0206-3 · Cited by 81
Inzucchi, S. E., Docherty, K. F., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., Solomon, S. D., Verma, S., Bělohlávek, J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1675 · Cited by 80
Current and emerging medications for overweight or obesity in people with comorbidities
Fujioka, K. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12502 · Cited by 76
“Phentermine/topiramate ER also impeded progression to T2D over 108 weeks (up to 76 and 79% in those without diabetes or those with prediabetes and/or metabolic syndrome at baseline, respectively, with the maximum dose of 15 mg/92 mg once daily) compared with placebo [54,55].”
MethodLong-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Liu, Y., Vu, V., & Sweeney, G. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00842 · Cited by 69
“Weight loss induced by a combination of lifestyle and pharmacological (phentermine/topiramate) interventions resulted in an increase in adiponectin levels in patients with metabolic syndrome (102, 103).”
BackgroundTao, T., Zhang, Y., Zhu, Y.-C., Fu, J.-R., Wang, Y.-Y., Cai, J., Ma, J.-Y., Xu, Y., Gao, Y.-N., Sun, Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa692 · Cited by 62
The Role of Anti-Inflammatory Adipokines in Cardiometabolic Disorders: Moving beyond Adiponectin
Jung, H. N., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413529 · Cited by 73
“Human levels of circulating adiponectin are positively affected by weight loss with a low-calorie diet [46]; medications, such as sibutramine or phentermine/topiramate [47,48]; and bariatric surgery [49].”
BackgroundBell, K., Shaw, J. E., Maple-Brown, L., Ferris, W., Gray, S., Murfet, G., Flavel, R., Maynard, B., Ryrie, H., Pritchard, B., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108188 · Cited by 64
Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.
Wilding, J. P. H., Calanna, S., & Kushner, R. F. (2021) · PubMed · doi:10.1056/nejmc2106918 · Cited by 39
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
“A vast body of evidence confirms that appro‑ priate management of obesity can postpone the progression from prediabetes to T2D and improve hyperglycaemia in patients with T2D [32–34].”
BackgroundKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis
Merlotti, C., Morabito, A., Ceriani, V., & Pontiroli, A. E. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0624-9 · Cited by 64
“In addition, these meta-analyses did not consider phentermine/topiramate controlled release, a new weight loss-promoting drug, which has shown effective results in prevention of type 2 diabetes together with weight loss [29].”
BackgroundGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
Self-citationTowne, S. D. C., Jr., Bolin, J. N., Ferdinand, A. O., Nicklett, E. J., Smith, M. L., & Ory, M. G. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14050464 · Cited by 60
“Thus, efforts must be carried out to encourage potentially at-risk individuals to undergo diabetes screening in order to detect metabolic syndrome [36,37] or pre-diabetes at early stages where diabetes may be prevented [37].”
BackgroundIs the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?
Lundqvist, M., Almby, K. E., Abrahamsson, N., & Eriksson, J. W. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00457 · Cited by 60
Remission of Recently Diagnosed Type 2 Diabetes Mellitus With Weight Loss and Exercise
Ades, P. A., Savage, P. D., Marney, A. M., Harvey, J., & Evans, K. A. (2015) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000106 · Cited by 55
Evidence for the Prevention of Type 2 Diabetes Mellitus
Shubrook, J. H., Chen, W., & Lim, A. (2018) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2018.158 · Cited by 54
Wilkinson, L., Yi, N., Mehta, T., Judd, S., & Garvey, W. T. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003232 · Cited by 47
Self-citationHankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15269 · Cited by 44
Self-citationFlores-Guerrero, J. L., Connelly, M. A., SHALAUROVA, I. Y., Gruppen, E. G., Kieneker, L. M., Dullaart, R. P. F., & Bakker, S. J. L. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.11.009 · Cited by 44
Flores-Guerrero, J. L., Gruppen, E. G., Connelly, M. A., SHALAUROVA, I. Y., Otvos, J. D., Garcia, E., Bakker, S. J. L., & Dullaart, R. P. F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092781 · Cited by 44
Garvey, W. T., Garber, A. J., Mechanick, J. I., Bray, G. A., Dagogo-Jack, S. E., EINHORN, D. F., Grunberger, G., Handelsman, Y., Hennekens, C. H., Hurley, D. L., et al. (2014) · Endocrine Practice · doi:10.4158/ep14279.cs · Cited by 45
Self-citationCombination therapy for obesity
Wilding, J. P. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117737401 · Cited by 37
“…physical activity, with effect sizes ranging from 10.9% in uncomplicated obesity to 8% in patients with obesity and type 2 diabetes in trials of up to one year in duration (Garvey et al., 2014a); there was a tendency for slight weight regain in trials with longer follow-up (Garvey et al., 2014a).”
BackgroundInfluentialGuo, F., & Garvey, W. T. (2017) · Diabetes Care · doi:10.2337/dc17-0088 · Cited by 37
Self-citationCost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective
Olivieri, A., Muratov, S., Larsen, S., Luckevich, M., Chan, K., Lamotte, M., & Lau, D. C. W. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01467-w · Cited by 38
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
“A sub-analysis from the CONQUER study further exami ned data from participants at high risk for progression to T2DM, namely those wit h IFG or IGT, as well as those meeting MetS criteria[102].”
MethodObesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.003 · Cited by 46
Clinical Definition of Overweight and Obesity
Garvey, W. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-95655-8_7 · Cited by 46
Self-citationMcLeod, M., Stanley, J., Signal, V., Stairmand, J., Thompson, D., Henderson, K., Davies, C., Krebs, J., Dowell, A., Grainger, R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05261-x · Cited by 36
Diet and Obesity-Induced Methylglyoxal Production and Links to Metabolic Disease
Hernandez-Castillo, C., & Shuck, S. C. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00221 · Cited by 37
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
Pharmacotherapy of Obesity: Limits and Perspectives
Rosa-Gonçalves, P., & Majerowicz, D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00328-6 · Cited by 34
Cardiovascular Effects of the New Weight Loss Agents
Vorsanger, M., Subramanyam, P., WEINTRAUB, H. S., Lamm, S. H., Underberg, J. A., Gianos, E., Goldberg, I. J., & Schwartzbard, A. Z. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.007 · Cited by 33
Metadata
- Authors
- Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W.
- Affiliations
- University of Alabama at Birmingham (US)
- Pennington Biomedical Research Center (US)
- University of California San Diego (US)
- Monteagle Medical Center, San Francisco, CA
- Medical University of Graz (AT)
- Medpace (United States) (US)
- Vivus (United States) (US)
- Corresponding author
- Garvey, W. Timothy
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-03-08
- Volume
- 37
- Issue
- 4
- Pages
- 912-921
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4392900
- OpenAlex
- W2149822561
- Cited by
- 215
- References
- 42
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 17 · 2023: 20 · 2022: 14 · 2021: 16 · 2020: 19 · 2019: 17 · 2018: 22 · 2017: 16 · 2016: 14 · 2015: 20 · 2014: 15
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01CX000432)
- National Institutes of Health (5p60dk079626-05)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK-079626, P30DK079626)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes prevention, prediabetes, metabolic syndrome, obesity, weight loss, cardiometabolic risk factors, lifestyle modification, glycemic control, lipid profile, blood pressure, waist circumference
- MeSH terms
- Topiramate, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Female, Fructose, Humans, Life Style, Male, Middle Aged, Phentermine, Placebos, Prediabetic State, Anti-Obesity Agents, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.